Oral-Parenteral Conversion Factor for Morphine in Palliative Cancer Care: A Prospective Randomized Crossover Pilot Study

<table>Quotas of oral morphine-3-glucoronide and morphine concentration: M3O/MO and oral morphine-6-glucoronide and morphine concentration: M6O/MO (<svg height="10.8125" id="M7" style="vertical-align:-0.10033pt" version="1.1" viewbox="0 0 42.912498 10.8125" width="42.912498" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.8125)">
<g transform="translate(72,-63.35)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="27.969212" y="0">1</tspan>
</text>
</g>
</g>
</svg>).</table>

Pain Research and Treatment

fig2

Figure 2

Figure 2: Oral-Parenteral Conversion Factor for Morphine in Palliative Cancer Care: A Prospective Randomized Crossover Pilot Study 